Un symposium satellite ANRS -NIDA
Drug Use and HIV and HCV Infection: The Challenge and The Potential Solutions
lundi 21 juillet de 18h30 – 20h30 (Salle 103)
This satellite session will bring together researchers, institutional actors and community representatives to discuss the current context of prevention, harm reduction, access and barriers to treatment and therapy options for drug users. The session will also discuss HIV treatment in low and middle income countries and the implications and availability of new treatments for HCV. Finally the satellite will describe a number of specific ANRS and NIDA research projects in different regions of the world addressing some of the known gaps to improve prevention and treatment options.
Des remises de Prix
- IAS/ANRS Young Investigator Award – Special HIV Cure Prize en clôture du symposium HIV Cure le dimanche 20 juillet à 15h
- IAS/NIDA Award Presentation: HIV and Drug Use Research Fellowship le mercredi 23 juillet à 8h23 salle plénière
- IAS/ANRS Young Investigator Award le jeudi 24 juillet à 8h20 salle plénière
Un colloque soutenu par l’ANRS
International HIV/Viral Hepatitis Co-Infection Satellite Meeting
HIV/viral hepatitis: antiviral therapy development and implementation
vendredi 18 et samedi 19 juillet – Intercontinental Melbourne The Rialto
The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV-related liver disease, through dual antiviral activity.
Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free direct acting antiviral (DAA) regimens for HCV one available. However, several barriers to access and impact of new HCV therapies exist including low levels of HCV screening, limited liver disease staging and lack of HCV-specific education and training of HIV health professionals.
The focus of the meeting will be development of strategies to enhance implementation of viral hepatitis antiviral therapy, particularly in preparation for the highly effective interferon-free DAA regiments for chronic HCV.
Un lieu d’échanges: le stand France
n°310 – rez-de-chaussée du Centre d’exposition — Ce stand rassemble l’ensemble des acteurs de la lutte contre le VIH/Sida. C’est un lieu d’échanges et de rencontres pour l’ensemble des francophones actifs dans ce domaine.